Skip to content

2027 at other companies

Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s 2027?
Exagen Inc. (XGN) reported 2027 of $3.45M in Q1 2026.
How has Exagen Inc.'s 2027 changed year-over-year?
Exagen Inc.'s 2027 decreased by 84.1% year-over-year, from $21.66M to $3.45M.
What is the long-term trend for Exagen Inc.'s 2027?
Over 5 years (2020 to 2025), Exagen Inc.'s 2027 has grown at a 16.1% compound annual growth rate (CAGR), from $1.76M to $3.7M.